OCEANSIDE, California – The Oceanside company that makes Remdesivir COVID-19 announced on Monday that the price of the drug will continue.
Gilead Sciences said a single dose of Remdesivir will cost $ 390. A typical course of treatment requires six ampoules administered for five days in a hospital intensive care unit. This means that a typical five day treatment will cost $ 2,340 per patient. However, that price is only available to the United States government, which temporarily manages distribution to hospitals due to lack of availability. For patients covered by private insurance, the price will jump to $ 520 per vial, which equates to $ 3,120 per patient – almost a thousand dollars more.
Remdesivir is approved only for seriously ill patients. It is administered intravenously and is the only drug to have an authorization for emergency use by the Food and Drug Adminisration to treat coronavirus infections.
According to experts in this field, the price set by Gilead is comparable to the cost of other ICU drugs. However, compared to the cheap and widely available corticosteroid dexamethasone, which costs a few dollars a day and is showing the same promise for COVID treatment, Remdesivir is much more expensive.
The Trump administration has accumulated half a million treatment courses with Remdesivir for distribution in hospitals across the country.
Suggest a correction